SIGN UP
LOG IN
MARKET
BGNE
BGNE
Beigene Ltd
NASDAQ
175.00
-4.36
-2.43%
After Hours: 175.00 0 0.00% 16:29 12/08 EST
OPEN
177.00
PREV CLOSE
179.36
HIGH
178.38
LOW
174.00
VOLUME
238.53K
TURNOVER
0
52 WEEK HIGH
280.62
52 WEEK LOW
156.56
MARKET CAP
18.30B
P/E (TTM)
-18.8885
1D
5D
1M
3M
1Y
5Y
Beigene Ltd: Current report
Press release · 2d ago
Investors in BeiGene (NASDAQ:BGNE) have seen notable returns of 33% over the past five years
Beigene, ltd. Shareholders are down 12% in the last quarter, but the stock is up over five years. Beigene's return of 33% is below the market return of 86%. Shareholders have made a profit over the last five years but the market is more focused on revenue growth. In the last 5 years beigene saw its revenue grow at 42% per year.
Simply Wall St · 4d ago
Tracking Baker Brothers Portfolio - Q3 2023 Update
Baker brothers' 13f portfolio value increased marginally from $17.28b to $ 17.35b in q3 2023. The largest five stakes in the portfolio are seagen, beigene, incyte, acadia pharma, and biomarin pharma. Stake increases were seen in rhythm pharma, abcellera biologics, and kymera therapeutics.
Seeking Alpha · 5d ago
Beigene Ltd: Statement of changes in beneficial ownership of securities
Press release · 5d ago
Weekly Report: what happened at BGNE last week (1127-1201)?
Weekly Report · 6d ago
Biotechs post record gains in November amid improving outlook
Healthcare biotechs post record gains in november amid improving outlook. Gene therapy developers outperformed and pharma giants look for m&a opportunities in the industry. November was the best month for biotechs since november 2020. The spdr s&p biotech etf climbed 14% in november while the healthcare sector rose only 9%.
Seeking Alpha · 6d ago
Zymeworks: Late-Stage Study Data In 2024 Makes This A Must Watch
Zymeworks inc. Showed positive results from the phase 1b/2 study using zanidatamab + chemotherapy + tislelizumab for the treatment of 1st-line her2-positive g/gejc. Results from a phase 3 herizon-gea-01 study are expected in 2024. Zymeworks has made great progress in advancing its pipeline. The company is incorporating the "5 by 5" strategy to advance multiple candidates.
Seeking Alpha · 12/01 21:06
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and BeiGene (BGNE)
TipRanks · 11/27 13:10
About BGNE
BeiGene, Ltd. is a global biotechnology company. The Company is focused on developing and commercializing oncology medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines including, BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. BRUKINSA is a second-generation small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) designed to maximize BTK occupancy and minimize off-target binding effects. It has obtained approvals to market BRUKINSA in the United States, China, the European Union, the United Kingdom, Canada and Australia. The Company has in-licensed the rights to distribute 13 approved medicines for the China market.
Webull offers Beigene Ltd (ADR) stock information, including NASDAQ: BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.